Acadian Asset Management LLC Taysha Gene Therapies, Inc. Transaction History

Acadian Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.43 - $3.25 $620,032 - $1.41 Million	-433,589 Reduced 94.24%	26,477 $75,000
Q4 2023 Feb 13, 2024	BUY	$1.33 - $2.88 $611,887 - $1.32 Million	460,066 New	460,066 $813,000
Q2 2023 Aug 07, 2023	SELL	$0.59 - $0.87 $197,356 - $291,017	-334,503 Reduced 82.53%	70,798 $46,000
Q1 2023 May 11, 2023	BUY	$0.65 - $2.3 $93,242 - $329,935	143,450 Added 54.78%	405,301 $321,000
Q4 2022 Feb 14, 2023	BUY	$1.39 - $2.98 $289,681 - $621,043	208,404 Added 389.93%	261,851 $590,000
Q2 2022 Aug 09, 2022	BUY	$2.47 - $6.77 $132,014 - $361,836	53,447 New	53,447 $199,000

119

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $119M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.